STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug
Shares of ProMis Neurosciences, developer of a treatment for Alzheimer’s disease, sold off sharply last week.
A closer look at the reason why — and whether it holds up.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.